Anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) increase the risk for thrombosis based on lupus anticoagulant positivity
10.1016/j.clinbiochem.2022.12.007 · doi-reference
Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) and PLT, APTT: Predictive value of thrombotic risk assessment in SLE patients
10.7754/clin.lab.2023.230526 · doi-reference
Thrombin generation test as a useful tool for improving disease severity stratification in antiphospholipid syndrome
10.1136/rmdopen-2025-005489 · doi-reference
Neutrophil extracellular traps mediate deep vein thrombosis: from mechanism to therapy
10.3389/fimmu.2023.1198952 · doi-reference
Risk factors for thrombotic events in systemic lupus erythematosus patients with antiphospholipid antibodies: insights from morphometric measurements of carotid arteries
10.3389/fcvm.2024.1373097 · doi-reference
Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome
10.3389/fimmu.2025.1527554 · doi-reference
Real-world treatments and thrombotic events in polycythemia vera patients in the USA
10.1007/s00277-023-05089-6 · doi-reference
Can complement activation be the missing link in antiphospholipid syndrome
10.1093/rheumatology/keae178 · doi-reference
Factors associated with venous and arterial thrombosis in patients with systemic lupus erythematosus: A systematic review and meta-analysis
10.1016/j.thromres.2025.109572 · doi-reference
Clinical-pathological characteristics of renal injuries identify different clusters in patients with antiphospholipid antibodies
10.1016/j.ekir.2023.01.018 · doi-reference
GAPSS: the global anti-phospholipid syndrome score
10.1093/rheumatology/kes388 · doi-reference
The role of neutrophil extracellular traps (NETs) in the pathogenesis of systemic lupus erythematosus and antiphospholipid syndrome
10.3390/ijms241713581 · doi-reference
Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones
10.1093/rheumatology/kead603 · doi-reference
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort
10.1016/j.semarthrit.2019.04.009 · doi-reference
SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis
10.1007/s10067-022-06497-1 · doi-reference
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
10.1002/art.34473 · doi-reference
Long-term incidence, risk factors and complications for venous thromboembolism in patients with systemic lupus erythematosus
10.1177/09612033241247359 · doi-reference
Non-criteria antiphospholipid antibody profiles and thrombotic outcomes in a cohort of patients with systemic lupus erythematosus
10.1136/lupus-2024-001174 · doi-reference
Management of anticoagulation in antiphospholipid syndrome and systemic lupus erythematosus with concurrent thrombosis and hemorrhage
10.7759/cureus.87122 · doi-reference
Worse cardiovascular and renal outcome in male SLE patients
10.1038/s41598-023-45171-7 · doi-reference
Risk factors for recurrent thrombosis in patients with antiphospholipid syndrome-a single-centre cohort study
10.1055/a-2646-9016 · doi-reference
Cigarette smoking and atherosclerotic cardiovascular disease
10.5551/jat.rv22015 · doi-reference
An antiphospholipid antibody profile as a biomarker for thrombophilia in systemic lupus erythematosus
10.3390/biom13040617 · doi-reference
Development of a risk prediction model for the first occurrence of thrombosis in patients with OAPS
10.3389/fimmu.2024.1459548 · doi-reference
Case report: In situ pulmonary artery thrombosis in a 12-year-old girl classified as systemic lupus erythematosus
10.3389/fped.2024.1341188 · doi-reference
Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics
10.1038/s41392-025-02168-0 · doi-reference
Assessment of 2023 ACR/EULAR antiphospholipid syndrome classification criteria in a Spanish cohort
10.1515/cclm-2025-0508 · doi-reference
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial
10.1182/bloodadvances.2024014415 · doi-reference
The 2023 ACR/EULAR antiphospholipid syndrome classification criteria
10.1002/art.42624 · doi-reference
Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity
10.1007/s11845-023-03519-y · doi-reference
